{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"4"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"3"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"14"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"6"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"5"},{"groupId":"OG020","value":"14"}],"units":"Participants"}],"description":"A DLT was graded using the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.02 and defined as any of the following: grade 3 or 4 non-hematologic adverse events unless they were not optimally treated with supportive care; grade 3 or 4 asymptomatic laboratory abnormal values lasting \\>7 days; prolonged grade 2 toxicity (lasting more than 2 weeks) leading to treatment interruption and/or dose reduction; pancytopenia with a hypocellular bone marrow and no marrow blasts lasting ≥6 weeks (AL participants); grade 3 neutropenia with fever or infection (OHM participants); grade 3 thrombocytopenia with bleeding (OHM participants); or grade 4 neutropenia or thrombocytopenia, regardless of symptoms and lasting ≥3 days (OHM participants).","groups":[{"description":"Participants received 10 mg MK-8628/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG000","title":"AL 10 mg QD 14-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG001","title":"AL 20 mg QD 14-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG002","title":"AL 40 mg QD 14-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.","id":"OG003","title":"AL 20 mg BID 21-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG004","title":"AL 80 mg QD 14-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.","id":"OG005","title":"AL 40 mg BID 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG006","title":"AL 120 mg QD 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG007","title":"AL 120 mg QD 21-21"},{"description":"Participants received 160 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG008","title":"AL 160 mg QD 14-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG009","title":"AML de Novo 80 mg QD 14-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG010","title":"AML/MDS 80 mg QD 14-21"},{"description":"Participants received 10 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG011","title":"OHM 10 mg QD 21-21"},{"description":"Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG012","title":"OHM 20 mg QD 21-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG013","title":"OHM 40 mg QD 21-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG014","title":"OHM 80 mg QD 21-21"},{"description":"Participants received 40 mg MK-8628/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.","id":"OG015","title":"OHM 40 mg BID 21-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.","id":"OG016","title":"OHM 120 mg QD 21-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG017","title":"OHM 120 mg QD 14-21"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.","id":"OG018","title":"OHM 120 mg QD 5-7"},{"description":"Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle.","id":"OG019","title":"OHM 120 mg QD 7-21"},{"description":"Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.","id":"OG020","title":"OHM/DLBCL 80 mg QD 14-21"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 85% of the intended dose of study therapy during the first cycle (i.e. \\>12 days at full dose for AL and \\>18 days at full dose for other hematological malignancies) or discontinued from the study due to a DLT attributable to study therapy.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Up to 21 days)","title":"Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}